Ariadne (Dimoxamine, α-Et-DOM), 4C-D, a-ethyl-2C-D, or 4-methyl-2,5-dimethoxy-alpha-ethylphenethylamine, 2,5-dimethoxy-4-methyl-butanphenamine, a-Et-2C-D, is a lesser-known psychedelic drug. It is a homologue of 2C-D and DOM. Ariadne was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin reported testing Ariadne up to a dose of 32 mg, and reported that it produces psychedelia at a bare threshold. Very little data exists about the pharmacological properties, metabolism, and toxicity of Ariadne in humans apart from Shulgin’s limited testing.
However, in more recent animal studies, α-Et-DOM was shown to produce stimulus generalisation in rats trained to respond to the drug MDMA. This suggests that while α-Et-DOM may lack hallucinogenic effects, it might potentially produce empathogenic effects similar to those of MDMA if used at higher dose ranges, beyond those trialled by Shulgin (the potency of α-Et-DOM in this study was similar to that of MDMA, 1.5 mg/kg, which would equate to a dose of ~100 mg in a human).